CohBar Confirms Anti-fibrotic Effect of a Novel Peptide in a Therapeutic Model of Idiopathic Pulmonary Fibrosis
December 16, 2019 09:00 ET
|
CohBar, Inc.
MENLO PARK, Calif., Dec. 16, 2019 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related...